Advanced search×

Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis.

Anand Kumar, Ryan Zarychanski, Bruce Light, Joseph Parrillo, Dennis Maki, Dave Simon, Denny Laporta, Steve Lapinsky, Paul Ellis, Yazdan Mirzanejad, Greg Martinka, Sean Keenan, Gordon Wood, Yaseen Arabi, Daniel Feinstein, Aseem Kumar, Peter Dodek, Laura Kravetsky, Steve Doucette, and Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group

Crit Care Med 38(9):1773-85 (2010) PMID 20639750

Septic shock represents the major cause of infection-associated mortality in the intensive care unit. The possibility that combination antibiotic therapy of bacterial septic shock improves outcome is controversial. Current guidelines do not recommend combination therapy except for the express purpose of broadening coverage when resistant pathogens are a concern.

DOI: 10.1097/CCM.0b013e3181eb3ccd
Version: za2963e q8za1 q8zb7 q8zc0 q8zd8 q8zec q8zf9 q8zg7
Buy PDF

Similar articles you may find interesting…

  1. A Randomized Controlled Trial comparing the efficacy of low-dose amitriptyline, amitriptyline with pindolol and surrogate placebo in the tre...
    A M Agius, N S Jones, and R Muscat

    Rhinology 51(2):143-53 (2013) PMID 23671895

    Patients often present to otolaryngologists with chronic facial pain, presumed to be of sinus origin despite normal nasal endoscopy and sinus CT. This pain has increasingly been recognized as being of neurological origin with one of the commonest underlying causes being mid-facial se...
    Buy PDF
  2. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies.
    Prithviraj Bose, Gary L Simmons, and Steven Grant

    Expert Opin Investig Drugs (2013) PMID 23647051

    Cyclin-dependent kinases (CDKs) regulate cell cycle progression. Certain CDKs (e.g., CDK7, CDK9) also control cellular transcription. Consequently, CDKs represent attractive targets for anticancer drug development, as their aberrant expression is common in diverse malignancies, and CDK inhibition ca...
    Buy PDF
  3. Virologic response during up to 2 years of entecavir plus adefovir combination therapy in multiple drug-refractory chronic hepatitis B patie...
    Young-Suk Lim, Ji-Young Lee, and Dong Jin Suh

    Antimicrob Agents Chemother (2013) PMID 23650172

    One year trial with entecavir plus adefovir resulted in a higher rate of virological response (VR) compared with lamivudine plus adefovir in multiple drug-refractory chronic hepatitis B (CHB) patients. This extension study enrolled 89 of 90 patients who completed a 52-week randomized...
    Buy PDF